Clinical Trials Logo

Colorectal Cancer (CRC) clinical trials

View clinical trials related to Colorectal Cancer (CRC).

Filter by:

NCT ID: NCT00977613 Completed - Clinical trials for Colorectal Cancer (CRC)

Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients

Start date: April 2007
Phase: N/A
Study type: Interventional

Given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage II and III colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.

NCT ID: NCT00851045 Completed - Clinical trials for Colorectal Cancer (CRC)

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer

NCT ID: NCT00483080 Completed - Clinical trials for Colorectal Cancer (CRC)

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic colorectal cancer patients treated with NGR-hTNF as single agent. Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.

NCT ID: NCT00165854 Completed - Clinical trials for Colorectal Cancer (CRC)

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.